Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics AntigenID

Cancer Genetics has launched a neoantigen discovery service it calls AntigenID designed to identify neoantigens and neoantigen signatures that can accelerate immuno-oncology drug discovery, predict patient-specific immune therapy response, and help create personalized immuno-vaccines. AntigenID incorporates genomic and transcriptomic profiles, HLA typing, and bioinformatic strategies, the company said.